Diabetic nephropathy
Conditions
Interventions
astragalus decoction andvalsartan group:astragalus decoction, valsartan
valsartan andthe placebo:valrtan,placebo
Sponsors
Shanghai Putuo District Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Exact 2 type diabetes history; 2. TCM syndrome differentiation: Qi-Yin vital essence deficiency patients; 3. Blood pressure is controlled under 140/90 mmHG, glycosylated hemoglobin < 7%, at the me time, GFR =60 ml/min/1.73 m2; 4. Lead period: drug regulation: high blood pressure drugs: for patients with high blood pressure, CCB category preparation is the first choice drug. If the blood pressure cannot be controlled in the targeted range, add antihypertensive drugs such as central or receptor antagonists. Do not take ACEI ARB categories antihypertensive drugs. Mean, do not take other Chinese medicine Chinese patent medicine which has the function of lowering protein. 2 weeks lead period, at the ning the end of the lead period, patients need conduct the following tests patients meet these two standards can enter the trial period: (1) Urinary albumin creatinine ratio: 30-300mg/mmol; (2) blood pressure to be controlled in the range of 90/60 mmHg to 140/90mmHg; (3) Fasting blood-glucose 3.8 to 7.8 mmol/L or non-fasting blood glucose=11.1mmol/L; 5. Aged 18 -75 years old; 6. Patients accept this drug treatment voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1) I Type diabetic; 2) Patients combined with severe primary diseases in heart, brain, liver hematopoietic tems; 3) Patients with diabetes mellitus ketoacidosis acute metabolic disorders within a month; 4) Acute renal failure patients combined with urinary tract infection, menstrual period, strenuous exercise, catch cold other stress states; 5) Psychotic, pregnant or lactating women; 6) Patients with known drug allergies; patients are participating in other drug clinical trials or have participated in other trails within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| UACR;eGF; | — |
Secondary
| Measure | Time frame |
|---|---|
| Scr;BUN;BUA;GFR;24-hour urinary protein quantity;Fasting plasma glucose;Postprandial blood glucose 2 h;Fasting c-peptide;Postprandial 2 h C peptide;Glycated hemoglobin; | — |
Countries
China
Contacts
Public ContactWang Yunman
Shanghai Putuo district Central Hospital
Outcome results
None listed